ReviewCurrent urology reports2014
Role of radical prostatectomy in clinically non-organ-confined prostate cancer.
Review in Current urology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review.Prostate cancer and prostatic diseases · 2024Pooled it
- Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis.World journal of surgical oncology · 2022Pooled it
- Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.Frontiers in oncology · 2024Article
- Role of surgery in oligometastatic prostate cancer.Prostate international · 2019Review
- Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary.Current urology reports · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In patients with lymph node-positive and metastatic prostate cancer there is currently no consensus about the best possible management. Multimodal approaches including systemic and local treatment have shown to improve survival. However, the role of radical prostatectomy (RP) is currently unclear. While treatment of the primary tumor is recommended in highly selected lymph node-positive prostate cancer patients, no prospective data exist to support resection of the primary tumor in metastatic patients as a treatment modality to improve overall survival. However, recent observational studies have suggested a survival benefit after prostate tumor cytoreduction. This article reviews existing evidence on the role of RP in lymph node-positive and metastatic prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.